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ABSTRACT 
Diabetics suffer unique microvascular and macrovascular complications thought to result 
from chronic hyperglycemia. Numerous studies examining the microbiological 
underpinnings for these · complications have observed that the upregulation of PKC 
activity is prevalent in affected tissues and cells of diabetics ; this upregulation has been 
implicated in the pathophysiology of the complications. Of the cells studied , little 
research has been directed towards neutrophils. This study looked for and examined the 
nature of the relationship between hyperglycemia and PKC in neutrophils. METHODS: 
Neutrophils were isolated from the blood samples of 13 diabetic and 13 matched healthy 
control subjects using a discontinuous Ficoll-Hypaque gradient system. Neutrophils were 
either lysed immediately or following incubation in a high-glucose medium or non-
glucose medium for times of 15 min to 6 hrs. The whole cell lysate was separated by gel 
electrophoresis and transferred to a PVDF membrane and Western blot performed. PKC 
activity was qualitatively determined by measuring the density of bands (representing 
phospho-PKC) on an x-ray film exposed to a chemiluminescence complex that included 
an antibody specific to the phosphorylated form of PKC~ll. RESULTS : Basal PKC 
lll 
activity was greater in diabetics than healthy controls and this activity displayed a higher 
correlation with Fasting ~lasma Glucose than HbA 1c (0.9379 vs. 0.7385, respectively). 
Incubating neutrophils in high-glucose medium (25mmol/L) increased PKC activity 
compared to basal activity and non-glucose medium incubation. This upregulation was 
observed to a similar degree in both diabetics and healthy controls and was maintained 
for up to 6 hrs of incubation without any significant deregulation. CONCLUSIONS: The 
activity of PKC~ll isoform in neutrophils of diabetics is increased and maintained 
chronically additionally, this effect is determined by hyperglycemia per se, independent 
of whether the subject is type 1 or 2 diabetic or non-diabetic. 
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INTRODUCTION 
Diabetes mellitus is a condition affecting 177 million people worldwide and causing the 
deaths of 4 million people each year. Complications arise in diabetics, both of a 
microvascular and macrovascular nature. The incidence and progression of diabetic 
complications is causally linked to hyperglycemia and metabolic control [I]. 
Incidentally, periodontal disease is an extension of the classic hyperglycemia-induced 
medical complications [2]. Several studies have shown that diabetics exhibiting poor oral 
hygiene suffer greater periodontal breakdown than non-diabetics under otherwise similar 
conditions [2, 3]. Although diabetes does not initiate periodontal tissue breakdown, it is 
considered a risk factor in its development and progression [4]. As a result, it would be 
prudent to examine the inflammatory response to periodontal microbiota in the presence 
of chronic hyperglycemia. 
A direct correlation between glycemic control and the severity of diabetic complications 
exists at a molecular and biochemical level [ 5]. An example to this phenomenon is the 
formation of advanced glycation end products induced by increased glycosylation of 
proteins [6]. In addition, previous work from our laboratory has demonstrated that 
neutrophils of diabetics' exhibit increased superoxide formation and that deteriorating 
glycemic control regardless of the type of diabetes worsens this phenomenon. In 
response to hyperglycemia, other studies have also shown that neutrophils can become 
activated or primed and hyper-react to stimuli [7]. 
Priming is a natural and necessary response to certain agonists, whereby particular 
biochemical and molecular processes occur to place the cell in a state of readiness [8]. 
One of these processes is the activation of protein kinase C (PKC). PKC is an integral 
part of the intracellular signaling network whereby events occurring outside the cell can 
induce responses within the cell following stimulation of membrane receptors. The PKC 
family of enzymes is comprised of at least 11 isotypes, each exhibiting individual 
anatomical characteristics, distinct distribution patterns, and varied substrate activity or 
cellular response. These isotypes are subdivided into 3 classes: (a) conventional or 
classic PKCs (cPKC), (b) novel PKCs (nPKC), and (c) atypical PKCs (aPKC). Defending 
the body from a bacterial insult requires a prolonged inflammatory response and the 
sustained activation of PKC is essential to this response; however, an unusually extended 
activation of PKC or an activation unrelated to a bacterial insult will result in an 
abnormal host cell response and unnecessary pathology. Hyperglycemia, for instance, 
has been shown to cause a chronic activation of PKC and is associated with diabetic 
vascular abnormalities. 
It is hypothesized here that the levels of phospho-PKC, which indicate the activity of 
PKC, observed in diabetic neutrophils relates to presence and severity of hyperglycemia. 
The study that is the subject of this paper seeks to show that via upregulation of activated 
PKC, hyperglycemia has a priming effect on neutrophils. This upregulation exists 
notwithstanding whether the subject is type 1 or type 2 diabetic or non-diabetic; 
therefore, one can hypothesize that the neutrophil dysfunction observed in diabetics is not 
a genetic, but rather an acquired abnormality caused specifically by its hyperglycemic 
environment. 
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2. BACKGROUND 
2.1 DIABETES MELLITUS 
Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia , which 
is caused by the deficient action of the hormone insulin. Such deficiency is caused by 
defects in the production of insulin , or diminished response of target tissues to insulin. 
Commonly , the aforementioned defects are simultaneously present, and it is not evident 
which defect is the primary cause of hyperglycemia. 
Insulin is required to convert foods into energy; thus , as a result of the defects , diabetics 
suffer abnormalities in the metabolism of fats , carbohydrates and proteins. Consequently , 
diabetics are susceptible to the effects of acute and chronic hyperglycemia. The signs 
and symptoms of chronic hyperglycemia include: (a) polyuria , (b) polydipsia , ( c) weight 
loss, (d) polyphagia , and (e) blurred vision while acute hyperglycemia can result in 
ketoacidosis or nonketotic hyperosmolar syndrome, both of which can result in death. In 
addition, diabetics suffer an increased susceptibility to infectious diseases , inflammatory 
disorders and wound healing complications. 
There are four major forms of diabetes: (a) Type I , (b) Type 2, (c) gestational diabetes 
and ( d) pre-diabetes. The vast majority of diabetics fall into the categories of Type I and 
Type 2. 
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In America, the prevalence of type 1 and type 2 diabetes has risen dramatically over the 
past two decades. From 1976 to 1994 the incidence of diabetes in adults rose from 8.9 -
12.3 percent [9]. Although both type 1 and 2 are becoming more prevalent, the incidence 
of type 2 is expected to rise more quickly due to increased obesity and decreased physical 
activity [1 O]. Diabetes is seen equally in men and women. With respect to ethnic 
groups, the prevalence of diabetes is two-fold greater in African-Americans, Hispanic-
Americans and than in White Americans of the dame age [9]. · 
2.1.1 TYPE 1 DIABETES 
Type 1 diabetes was previously referred to as insulin dependent or juvenile-onset diabetes 
as it is usually diagnosed in children or young adults. It is characterized by the 
autoimmune destruction of the pancreatic beta cells [11]. This destruction is varied; that 
is, it can be fast or slow, complete or partial. Consequently , there is a variable deficiency 
in the production of insulin, and thus in the rate of onset and the severity of symptoms 
[12]. Untreated , Type 1 diabetics commonly display classic signs and symptoms of 
chronic or acute hyperglycemia [12]. Type 1 diabetics require insulin injections to 
survive, because they have an absolute insulin deficiency; thus , what little production of 
insulin remains is insufficient for glucose metabolism. 
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2.1.2 TYPE 2 DIABETES 
Type 2 diabetes was previously classified as non-insulin dependent diabetes or adult-
onset diabetes. The etiology of this form of diabetes ranges from pre-dominantly an 
insulin resistance with relative insulin deficiency to predominantly an insulin secretory 
defect with insulin resistance [13]. Type 2 diabetics suffer a relative rather than absolute 
insulin deficiency [14]and at least initially, if not throughout their lives, do not require 
insulin injections to survive. Because the hyperglycemia develops slowly, the classic 
symptoms are often not expressed and the condition can go undiagnosed for years. 
Nevertheless, this group is still at increased risk for developing the classic macrovascular 
and microvascular complications (see Complications of Diabetes). In contrast to Type 1 
diabetes, the risk of developing this form of diabetes is associated with increased age, 
obesity, and lack of physical activity [10]. 
2.1.3 GLUCOSE DIAGNOSIS AND MONITORING 
The American Diabetes Association (ADA) has established guidelines for the diagnosis 
and management of diabetes. These criteria were last updated in 2003 [ 15]. 
Three tests are currently available to test diabetes: (a) oral glucose tolerance test (OGTT), 
(b) fasting plasma glucose (FPG) , and ( c) HbA 1c. The initial screening test undertaken is 
the FPG. It measures glucose in the blood after 8 hours of fasting. Although , an FPG 
greater than 126 mg/di is diagnostic of diabetes, any reading of 110 to 126mg/dl indicates 
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the need of the OGTT to determine the degree of glucose intolerance. The FPG must 
then be confirmed by repeating the test on a subsequent day. Neither the HbA 1c or the 
OGTT are used for initial screening as they are both poorly reproducible and the latter is 
impractical and expensive as well [ 15]. 
Glycemic control is fundamental in the management of diabetes. Both the test for 
glycated hemoglobin (HbA 1c) and self-blood glucose monitoring are crucial in 
accomplishing this goal[15]. The HbA 1c test measures the percentage of glycated 
hemoglobin; glucose in the bloodstream can become attached to the hemoglobin in red 
blood cells by a process referred to as glycosylation [16]. Once hemoglobin becomes 
glycated , it remains that way for the life of the red blood cell, which is a three to four 
month period. 
The Diabetes Control and Complications Trial (DCCT) found that the HbA 1c test is the 
best method of assessing blood glucose levels for the past 3 months, but, because the 
HbA 1c value represents mean glycemic levels over a 2-3month period , metabolic control 
is best judged by also considering the patients self-blood glucose test results. While self-
blood glucose monitoring is useful for controlling hyperglycemia on a daily level and 
preventing hypoglycemia , the HbA1c test is important to evaluate the mean glycemic 
level and is a good indicator of the risk of developing long- term complications . Both the 
DCCT and the United Kingdom Prospective Diabetes Study Group (UKPDS) found that 
there was a significant reduction in micro- and macrovascular complications with 
lowered HbA 1c [l , 17, 18]. The ADA recommends an HbA 1c of7 ,0 percent [15]. People 
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without diabetes typically have a level of 5 percent. Levels above 6.5 - 7 percent indicate 
decreasing levels of metabolic control. The goal of diabetic management is to achieve a 
level of metabolic control similar a person without diabetes [15]. 
2.1.4 COMPLICATIONS OF DIABETES 
The signs and symptoms of diabetes are the direct result of hyperglycemia. Likewise, the 
systemic complications of diabetes are associated with prolonged hyperglycemia. As 
discussed earlier , poor glycemic control is associated with the incidence and progression 
of diabetic complications. The DCCT, completed in the mid 1990s, showed conclusively 
that people with Type 1 diabetes could reduce their risk of complications by as much as 
50 percent, if they kept their blood sugars as close to normal as possible , and the recent 
United Kingdom Prospective Diabetes Study found similar results for people with Type 2 
diabetes [ 14, 19]. Although the etiology of Type 1 diabetes differs from that of Type 2 
diabetes , the pathophysiology of the complications are similar and are associated with the 
effects of chronic hyperglycemia [ 14]. 
Long-term complications of diabetes mellitus have usually been classified into 2 major 
types: (a) macrovascular and, (b) microvascular. Macrovascular complications account 
for the majority of diabetic deaths [20]. These complications are due to many factors 
including hypertention , hyperglycemia and endothelial dysfunction [21]. Macrovascular 
complications are primarily the result of accelerated atherosclerotic disease that affects 
the large vessels of the body that supply the heart , brain and lower extremities. As a 
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result, diabetics are susceptible to myocardial infarction, stroke and limb, respectively. 
The pathogenesis of atherosclerosis in non-diabetics has been extensively described in 
recent reviews, and begins with endothelial dysfunction [22]. In diabetic arteries, 
endothelial dysfunction involves both insulin resistance and hyperglycemia. Insulin 
resistance results in decreased endothelial production of the anti-atherogenic molecule 
nitric oxide, and increased proliferation of vascular smooth muscle cells [23] and 
increased production of plasminogen activator inhibitor-I (PAI-1) [24]. Hyperglycemia 
itself also inhibits production of nitric oxide in arterial endothelial cells[25] and 
stimulates production of PAI- 1 [26]. 
Conversely, microvascular disease affects the small vessels, such as those supplying the 
retina, nerves , and kidneys [27]. End organ damage can lead to (a) diabetic retinopathy 
and blindness, (b) diabetic neuropathy , which , when combined with macrovascular 
disease , may result in lower limb amputation , and ( c) diabetic nephropathy , often leading 
to end-stage renal disease requiring dialysis or transplantation. In vivo and in vitro studies 
indicate that AGEs play a role in the pathogenesis of diabetic nephropathy and the 
progression of renal failure [28]; they have been found in increased amounts in the renal 
glomeruli of diabetics [29]. AGEs have a number of deleterious effects on the 
vasculature , including cross-linking of type IV collagen resulting in increased basement 
thickness , modification of matrix components , platelet aggregation , defective vascular 
relaxation due to decreased elasticity of vessel walls , abnormal lipoprotein metabolism , 
and induction of cytotoxic pathwa ys that may affect the pathophysiology of the vascular 
wall [28] 
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AGEs have also been implicated in the pathophysiology of diabetic neuropathy. Non-
enzymatic glycosylation produces crosslinkages of type 1 and lll collagens in the 
extracellular matrix resulting in physical alterations in the properties of the extracellular 
matrix (ECM). The changes render the environment unattractive to growing axons by 
reducing the ability of new axonal sprouts to bind to the ECM, hence leading to the 
observed regenerative failure [30]. In addition, glycation of type IV collagen in basal 
laminal tubes surrounding axonal sprouts renders the collagen less digestible by 
proteases. In normal axonal regeneration this tube should break down [31]. The 
persistence of these tubes in diabetics is thought to act as a physical barrier to axonal 
growth [32]. 
Hyperglycemia has also been linked to neuropathy via direct axonal damage. 
Hyperglycemia results in increased intracellular levels of sorbitol and fructose (see 
Biochemistry of Diabetic Complications) by the polypol pathway. This increase impairs 
the proper functioning of Schwarm cell ion pumps thus damaging them and subsequently 
leading to the demylenation of peripheral nerves observed in diabetics [33]. 
In addition to these classic diabetic complications , it is generally acknowledged that 
periodontal disease is included. 
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2.2 TWO-WAY INTERACTIONS BETWEEN PERIODONTAL DISEASE 
AND DIABETES MELLITUS 
Periodontitis is a chronic inflammatory condition affecting the periodontium or 
supporting tissues of the teeth. It is characterized by destruction of these supporting 
tissues with ensuing pocket formation recession or both. Both the microbes invading the 
tissues as well as the host's response to the invasion mediate this destruction. The 
importance of host response to periodontal disease progression is evident from studies of 
neutrophil dysfunction and severity of periodontitis [34-37]. Systemic disease can also 
be a factor for the onset and progression of periodontitis. Strong evidence exists to 
support findings that diabetic patients are at an increased risk for periodontitis. Studies 
have also found that diabetics do not always suffer greater periodontal breakdown when 
compared to non-diabetic controls [38]. Some general trends are evident: (a) 
uncontrolled and poorly controlled diabetes is associated with greater risk for periodontal 
disease, (b) periodontal disease is more frequent and severe among diabetics also 
suffering from other "classic" complications such as retinopathy, and ( c) increased 
susceptibility to periodontitis does not correlate with increased levels of plaque. [39-42] 
It has been demonstrated that diabetes affects all periodontal parameters, including 
bleeding scores, probing depths, loss of attachment and missing teeth [43]. In a 2-year 
longitudinal study Type 2 diabetics had a significantly greater risk for progressive 
alveolar bone loss when compared with non-diabetic subjects [ 44]. Additionally, Loe 
found that periodontal breakdown among Pima Indians with Type 2 diabetes was three 
times more likely when compared to healthy controls. Among the diabetics, those with 
retinopathy were five times more likely to have periodontitis than those without [2]. 
There is variability in the rate of development and severity of the periodontal 
complications with diabetics [ 41]. As well, previous microbiological studies have 
provided evidence that the suspected periodontal pathogens found in the microflora of 
diabetic individuals are not unique to them and are essentially similar to those present in 
systemically healthy adult periodontitis patients [ 45, 46]. These findings coupled with the 
DCCT and UKPDS findings that increased metabolic control decreased the incidence of 
diabetic complication, would suggest that metabolic control is a critical factor in 
assessing the risks of periodontal breakdown. 
Although the association is still unclear, there is evidence to suggest that periodontal 
infections can cause problems with glycemic control for diabetics and that the treatment 
of periodontal diseases can improve glycemic control. [47-49]. Iwamoto proposed that 
treating periodontal disease reduced the production of the cytokine, TNF-a, by 
monocytes in infected periodontal tissues. TNF-a has been shown to induce insulin 
resistance thus reducing serum TNF-a levels would consequently improve insulin 
resistance and metabolic control [ 50]. 
It has even been hypothesized that a two-way reciprocal interaction exists between 
diabetes and periodontal infections. The proposed mechanism for this interaction is based 
on increased production of the TNF-a. The elevated levels of circulating TNF-a 
observed in diabetics can account for the more severe periodontal disease seen m 
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diabetics. Exacerbated periodontal disease may further upregulate circulating TNF-a by 
stimulating monocytes, which, in tum, may have additive effects on insulin sensitivity in 
Type 2 diabetic patients [42, 51]. 
2.3 PATHOLOGY OF PERIODONTAL COMPLICATIONS IN DIABETICS 
A number of underlying factors are known to contribute to enhance periodontal 
destruction in diabetics. These include ( a) neutrophil dysfunction (b) altered collagen 
metabolism [52, 53] and collagen glycosylation [53], and (c) the chronic production of 
pro-inflammatory cytokines, TNF-a and IL-6 [51, 54, 55]. 
Hyperglycemia results in non-enzymatic glycation of proteins to form advanced 
glycation end products, AGEs. The AGEs stimulate the chronic production of the 
cytokines, TNF-a and IL-6, by phagocytes. Consequently, these cytokines may 
exacerbate preexisting periodontal disease in various ways, such as by stimulating 
fibroblasts to synthesize matrix-degrading enzymes and by stimulating osteoclasts to 
activate bone resorption [51]. It is yet still uncertain as to which of the hypothesized 
mechanisms or combinations of mechanisms is directly responsible for the pathogenesis 
of the complications or whether different mechanisms are operative in different tissues 
[56]. This paper will concentrate on the role of neutrophils. 
2.4 POLYMORPHONUCLEAR LEUKOCYTES (PMNS) 
Neutrophils , also known as polymorphonuclear leukocytes or PMNs , are the predominant 
leukocyte in blood , accounting for about two thirds of all blood leukocytes. They arise 
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from the differentiation of myeloid stem cell within the bone marrow. Unlike 
macrophages, with which they share a common progenitor, PMNs differentiate almost 
completely in the bone marrow and enter the tissues in a more mature state. This makes 
them suited for fast responses. As such, they are the primary phagocytic cells of the 
host's immune response to an acute bacterial insult. 
2.4.3 PMN FUNCTION 
PMN s must undergo a number of sequential steps to successfully meet a bacterial 
challenge. These are known as: (a) transendothelial migration , (b) chemotaxis , (c) 
phagocytosis , and ( d) killing. 
Transendothelial migration describes the movement of PMNs from the bloodstream into 
tissues [57]. It begins with rolling , whereby the leukocyte essentially pauses to inspect 
the luminal surface of the blood vessel's endothelium. In response to a bacterial insult in 
the surrounding tissues , a number of cytokines are released. These stimulate the 
endothelial cells to express selectin s, E-selectin and P-selectin, which bind to the 
leukocytes to further slow them down and chemokines , IL-8, to signal them the come to a 
stop and become firmly associated with the endothelium [57]. The adhesion process is 
enabled by the expression of the integrin , leukocyte function- associated antigen- I (LF A-
l) , on the PMN membrane that selectively binds to the adhesion molecule, intracellular 
adhesion molecule-2 (ICAM-2), located on the endothelium. This sets the stage for the 
neutrophil to migrate between the endothelial cells and into the tissues. 
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Once the cell has entered the connective tissue, it must locate and migrate to the site of 
the insult. A process known as chemotaxis accomplishes this. The PMNs are attracted to 
chemotaxins , such as TNF-a , IL-8 , IL-I , and complement protein C5a, for which it has 
receptors called G-protein coupled receptors (GPCR). When the leukocyte is within I to 
2 body lengths away from the microbe it can sense a concentration gradient that directs it 
to the target [58]. 
When the PMN has reached the pathogen it must ingest it by phagocytosis. The 
leukocyte membrane invaginates , and completely envelops the microbe into a 
membrane-d elineated structure , the phagosome. This process is facilitated by the 
presence of recognition molecules , ligands , located on the surface of the pathogen [59]. 
These ligands are called opsonins. After the pathogen is ingested it can be killed. This is 
accomplished by oxidative (respiratory burst) or non-oxidative ( degranulation) 
mechanisms . 
The oxidative mechanism can be used if the leukocyte is present in an aerobic 
environment. PMNs utilize the NADPH oxidase system to catalyze oxygen to reduced 
oxygen metabolites such as superoxide anion (0 2-). Consequently , this anion can form 
hydrogen peroxide , which , in turn , can be catalyzed by myeloperoxidase to form 
hypochlorous acid [ 60]. The non- oxidative killing mechanism is used in anaerobic 
conditions. It involves the fusing of the phagosome with a lysosome (a sac containing 
microbicidal components created by the PMN) to f01m a phagolysosome. The lysosome 
can then release its components ( degranulate) and complete the killing process . The 
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microbicidal enzymes and molecules released into the phagolysosome can also be 
released into the extracellular environment. Extracellular killing is important in the 
elimination of the invading microbes [35]. 
2.4.4 PMN PRIMING 
Although the neutrophil response is designed to restrict the damage to the smallest 
possible region where the pathogen is located, some of the damaging agents inevitably 
leak into the surrounding areas where they have the capacity to inflict collateral damage 
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on host tissues. Thus, it is essential that the host defense response of these cells be finely 
tuned to result in the appropriate level of response to any given situation. One of the 
regulatory mechanisms implicated in controlling neutrophil responses is priming [7]. 
Circulating neutrophils from healthy persons are unable to engage in oxidative or non-
oxidative killing when faced with a pathogen unless they have first been in contact with a 
priming agent. Agents such as tumor necrosis factor- [alpha] (TNF-a ), granulocyte 
macrophage colony stimulating factor (GM-CSF) platelet activating factor (PAF) or 
endotoxin , agents that themselves fail to induce respiratory burst activity or 
degranulation, cause a dramatic increase in the response of PMN s to secondary agonists 
[61]. And thus the neutrophil is 'transformed' from a quiet, non-secretory cell to one that 
is highly motile and hyper-responsive. 
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Priming of neutrophils by agents unrelated to the presence of a pathogen has been 
implicated in the pathogenesis of complications in certain systemic disorders. There is 
some evidence to suggest that particular diseases can predispose PMN s to exist 
continually in a primed or hyper-responsive state. Such is found to be the case with 
localized aggressive periodontitis [34]. This also appears to be the case in diabetes 
mellitus. Advanced glycation end products formed as a result of hyperglycemia are 
increased in diabetes mellitus. Although they do not possess an ability to augment the 
neutrophil respiratory burst alone, AGEs do exert a dose-dependent enhancement on the 
neutrophil respiratory burst in response to a secondary mechanical or chemical stimulus 
[62, 63]. The translocation of protein kinase C, a key enzyme in transmembrane 
signaling , from the cytosol to the membrane is also thought to a part of the priming 
process [ 64] 
2.4.5 PMN DYSFUNCTION IN DIABETES MELLITUS 
Any defects in the steps from migration to killing, either acquired or innate, will modify 
neutrophil function and results in systemic or local problems with the immune response 
and increase host susceptibility to a range of infective agents [3 5]. Impaired PMN 
function has been found in patients with diabetes. All steps of PMN functioning are 
altered in diabetic patients , which may increase the risk of vascular complications and 
infectious episodes [65]. Defects in adherence [66, 67], chemotaxis [68-70], or 
phagocytosis [71, 72] have all been reported. These functional and biological events are 
related to the molecular and biochemical processes involved in diabetic abnormalities. 
16 
2.5 BIOCHEMISTRY OF DIABETIC COMPLICATIONS 
Theories on the biochemical pathways that lead to diabetic microvascular complications 
are emerging. The predominant well researched theories on how chronic hyperglycemia 
causes damage to the microvasculature include, but are not limited to: (a) increased 
polypol (sorbitol/aldose reductase) pathway flux, (b) formation of advanced glycation 
end-products (AGE), ( c) generation of reactive oxygen species (ROS), and ( d) activation 
of diacylglycerol and protein kinase C isoforms [5, 26, 27, 73, 74]. The relevance of each 
of these four pathways is supported by animal studies in which pathway-specific 
inhibitors preveht various hyperglycemia-induced abnormalities [5]. 
Aldose reductase is the first enzyme in the polypol pathway. This enzyme normally has a 
low affinity for glucose and in non-diabetics glucose metabolism via this pathway is 
minimal [5]. As intracellular glucose rises to hyperglycemic levels the aldose reductase 
pathway flux increases. The first step is the nicotinamide adenine dinucleotide 
diphosphate or NADPH-dependant reduction of glucose to sorbitol. Sorbitol is in tum 
oxidized to fructose via the enzyme sorbitol dehydrogenase using NAD as a cofactor. The 
most likely mechanism whereby this theory has its deleterious effect is the decline in 
cellular NADPH. NADPH is a cofactor required for regenerating reduced glutathione 
and its consumption could alter the redox balance causing increased intracellular 
oxidative stress [75] 
Glucose can also react non-enzymatically with proteins and other macromolecules to 
form Schiff bases which are then transformed into Amadori products [76]. The Amadori 
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products degrade into highly active compounds that can react with intra- and extracellular 
proteins to form AGE. This alteration of proteins by glucose is referred to as glycation. 
The formation and accumulation of AGE is a natural part of the aging process known as 
the Maillard reaction [27]. In diabetics, though, this accumulation is accelerated resulting 
in pathologic consequences. Intracellular hyperglycemia initiates the formation of 
intracellular and extracellular AGEs [77]. AGE can damage cells by impairing the 
normal function of a wide range of proteins. AGE can also alter cell function via 
interaction with cell membrane receptors such as receptor for AGE (RAGE) [6]. One 
type of AGE-RAGE interaction observed with phagocytes is the expression of cytokines 
such as TNF-a, PAF, and GM-CSF [51]. 
In the hexosamine pathway , glucose is metabolized to glucosamine via glucose-6-
phosphate and fructose-6-phophate [ 5]. The mam enzyme m this conversion 1s 
glutamine: fructose-6-phosphate amidotransferase [GFAT]. Glucosamine enhances the 
production of TGF-beta protein and the subsequent production of the matrix components 
heparin sulfate proteoglycan and fibronectin [78] The mechanism by which this pathway 
results in diabetic complications is thought to be through increased gene transcription and 
changes in protein function [26]. 
PKC and diacylglycerol are essential molecules for intracellular signaling. The DAG-
PKC signaling pathway is necessary for physiological cell responses to a variety of 
extracellular signals [79]. Activation of PKC occurs by the physiological receptor-
mediated phospolipase C or phospolipase D pathways. Pathological activation of PKC 
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can occur in diabetes in response to hyperglycemia by (a) the de novo synthesis of DAG 
from glycerol-3-phosphate (see Protein Kinase C below) [80, 81 ], (b) the binding of 
extracellular AGE to cellular receptors such as RAGE [82, 83], and ( c) increased 
oxidative stress induced by the polypol pathway [84]. PKC~ is the primary isoform 
activated in diabetes and in fact , elevated levels of PKC~ have been observed in the 
retina , aorta, and glomeruli of diabetic animals and patients [85]. 
These four seemingly distinct pathways have been known to be responsible for the 
pathogenesis of diabetic complications and specific inhibitors of each of the individual 
pathways ameliorate or prevent the pathology seen in diabetics[5]. Until recently there 
was no known common link between the four mechanisms. It is now hypothesized that 
the four pathways all reflect a single unifying hyperglycemia-induced process of 
overproduction of reactive oxygen species (ROS) by the mitochondrial electron-transport 
chain [5]. 
Hyperglycemia results in high glucose flux which can overwhelm the mitochondrial 
electron transport system [26, 74]. This results in mitochondrial production of ROS such 
as 0 2-, which can enter the cell nucleus and cause DNA strand breaks. These breaks 
cause the ribosylation and inactivation of glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) by the enzyme poly (ADP-ribose) polymerase (PARP). This inactivation of 
GAPDH blocks the complete metabolism of glucose and causes the accumulation of 
upstream glucose metabolites that are consequently shunted into the four major pathways 
discussed above [7 4]. 
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2.6 PROTEIN KINASE C 
PKC is an integral part of the intracellular signaling network whereby events occurring 
outside the cell membrane can induce responses within the cell following stimulation of 
membrane receptors [86]. The PKC family of enzymes comprises of at least 11 isotypes , 
each exhibiting individual anatomical characteristics , distinct distribution patterns , and 
varied substrate activity or cellular response. The catalytic domains are similar in all, as 
they are all serine/threonine kinases , but the regulatory domains differ with respect to 
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their requirements for the presence of the cofactors , DAG and Ca2+, for optimal catalytic 
activity [87]. This difference is used to subdivide the isotypes into 3 classes: (a) 
conventional or classic PKCs (cPKC) that are DAG sensitive and Ca2+ dependent , (b) 
novel PKCs (nPKC) that are DAG sensitive , but Ca2+ independent , and (c) atypical PKCs 
( aPKC) that are neither DAG sensitive or Ca2+ dependant. PK Ca and PKCPll are cPKCs 
[88]. 
Most PKCs are fully phosphorylated shortly after translation , but usually remam 
catalytically inactive due to the regulatory domain ' s cofactor requirements. In resting 
cells or in the absence of lipid hydrolysis , PKCs are localized primarily in the cytosol 
[87]. Activation results from the binding of DAG and increases the affinity of PKC for 
membrane phospholipids. As a consequence , not only is the residence time of PKC on 
the membrane increased , but also the conformational changes associated with 
phospholipid binding enables PKC to phosphorylate protein substrates [87]. 
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In vivo PKC activity is initiated by the binding of an agonist to its receptor on the cell 
membrane. The primary sources of DAG that activate PKC are derived from: (a) the 
hydrolysis of phosphatidylinositide (Pl) by phospholipase C (PLC) and (b) the 
metabolism of phosphatidylcholine (PC) by phospholipase D (PLD). 
Diacylglycerol is generated by the phospholipase C pathway when PI, which has been 
further phosphorylated to phosphatidylinositol 4,5-bisphosphate (PIP2), is hydrolyzed by 
PLC. In addition to the second messenger DAG, this lipid metabolism also generates the 
second messenger myo-inositol 1,4,5-trisphosphate (IP3), which results in the activation 
of membrane channels and the influx of extracellular calcium [87]. The DAG produced 
from PI hydrolysis is rapidly converted to phosphatidic acid (PA) by the action of DAG 
kinase, and further to PI, PIP, and PIP2 (PI turnover) [89]. 
The phospholipase D pathway generates DAG by the metabolism of phosphatidylcholine 
(PC) to phosphatidic acid (PA)[90]. The byproducts of PC hydrolysis are choline, which 
is rapidly phosphorylated to P-choline by choline kinase, and PA, which can be converted 
as in the PLC pathway to PIP2. 
Upon stimulation of cell surface receptors The PLC pathway rapidly produces DAG. As 
aforementioned, this DAG quickly disappears as it is converted to PA and eventually to 
PIP2 in the PI turnover. The level of DAG, however, often increases again with a 
relatively slow onset and longer duration of minutes and occasionally hours [91]. It is 
generally thought that this second wave of DAG appearance is the result of PC hydrolysis 
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in the PLD pathway [90]. Thus, a typical response pattern to stimulation is a biphasic 
increase in DAG characterized by an initial, rapid, transient peak followed by a more 
slowly developing, but prolonged, accumulation (Exton, 1994); the first peak due to PI 
hydrolysis and associated with an increase in inositol phosphates and cytosolic Ca2+ and a 
second phase due to PC hydrolysis with a concurrent rise in choline/P-choline levels [91]. 
In vitro, PKC can be activated by tumor-promoting phorbol esters such as phorbol 12-
myristate 13-acetate or PMA [79, 92]. PMA is a DAG analogue, thus this signal pathway 
bypasses the membrane receptors, and directly activates PKC [79], which leads to the 
assembly and activation of the NADPH oxidase on the inner surface of plasma 
membrane, without the transient rise in intracellular Ca2+. Studies involving PKC 
activation have been simplified by the use of phorbol esters but since PMA bypasses the 
in vivo mechanisms for PKC activation, it cannot be considered a physiological activator. 
In fact, PMA stimulation can activate many PKC isoforms and increase PKC activity by 
five to ten times. Hyperglycemia, on the other hand only activates a select few isoforms, 
of which PKC~ll is the primary one, and by just two times [85, 93]. 
A third source for DAG that has been proposed for diabetics is a hyperglycemia-induced 
pathway. Increases in DAG contents have been demonstrated in a variety of tissues 
associated with diabetic vascular complications, including retina, aorta, heart, and renal 
glomeruli [85]. In vitro, incubating rat vascular tissue in 22mM glucose media resulted 
in elevated cellular DAG contents [94]. In addition, this elevation can be maintained 
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chronically . Xia et al. [81] showed that DAG levels were elevated in the vascular tissues 
of diet-induced hyperglycemic dogs even five years after the return to a normal diet. 
Most studies have shown that the increase in cellular DAG contents in response to 
hyperglycemia or diabetes is not from the PLC or PLD pathways [85] but rather a de 
nova pathway. In this pathway glycolytic intermediates such as glyceraldehyde-3-
phospate and dihydroxyacetone phosphate are reduced to glycerol-3-phosphate. 
Subsequent stepwise acylation results in DAG synthesis [80, 81, 85, 94]. Evidence for 
this pathway comes from labeling studies that have found the incorporation of glucose 
into the structure of DAG in the aortic smooth muscle of dogs [81] and the renal 
glomeruli of non-diabetic rats [95]. It should be noted that the de novo pathway results in 
PKC activation in the absence any agonist-membrane receptor interaction. 
PKC is a key enzyme in transmembrane signal conduction. Intracellular signaling 
networks are crucial for cells as they allow the cells to communicate with and react to 
their environment. Because these networks control cell behavior , disruptions in their 
proper functioning can have pathological consequences. Several studies have 
demonstrated that hyperglycemia could cause its adverse effects by activating the 
diacylglycerol-sensitive protein kinase C [85]. PKC activity is increased in the retina[96 , 
97], aorta and heart [94, 98], and renal glomeruli [95], as well as in cultured vascular 
cells or tissues exposed to elevated levels of glucose [94, 99]. The importance of PKC in 
the development of complications of diabetes is evident from studies in which inhibitors 
(staurosporine , calphostin C, and GF109203X) or activators (PMA or hyperglycemia) of 
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PKC have been used to abrogate or reproduce the pathological changes associated with 
diabetes, respectively. One of the consequences of increased PKC activation is the 
production of reactive oxygen species (ROS) such as 0 2- via the enzyme nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase [100]. It has been shown that 
increased ROS production is related to impairment of endothelial function [94, 101-103]. 
Furthermore, NADPH induced production of ROS has been implicated in the 
pathogenesis of vascular smooth muscle hypertrophy [ 10 I]. 
The presence of abundant quantities of PKC in neutrophils suggests that this enzyme 
plays an important role in the function of this cell [ I 04]. Little information exists on the 
effect of hyperglycemia or diabetes on PKC activation in neutrophils. Saiepour et al 
[105] investigated the effects of elevated glucose concentrations on complement receptor-
and Fcgamma receptor-mediated phagocytosis in normal human neutrophils. They found 
that incubation of normal PMNs in D-Glucose at 15 or 25 mM dose-dependently 
inhibited both complement receptor- and Fcgamma receptor-mediated phagocytosis, as 
compared to that at a normal physiological glucose concentration. In addition, protein 
kinase C inhibitors GFI 09203X and Go6976 both dose-dependently and completely 
reversed this inhibitory effect. The authors concluded that elevated glucose 
concentrations could inhibit complement receptor and Fcgamma receptor-mediated 
phagocytosis in normal human neutrophils by activating PKCa and/or PKC~. 
A study examining neutrophil dysfunction, endothelial cells from healthy subjects were 
incubated in high glucose concentrations (over 27.8 mM) for 48 hrs and then incubated 
with PMNs. They found increased endothelial-neutrophil cell adhesion and expression of 
24 
endothelial adhesion molecules (intercellular adhesion molecule-I (ICAM-1), P-selectin, 
E-selectin). These events were found to be protein kinase C dependent, as PKC 
inhibitors, but not other intracellular second messenger inhibitors, significantly blocked 
this adhesion[} 06]. Oldenborg and Sehlin's [107] study on chemokinesis found that 
glucose induced activation of PKC attenuated insulin-stimulated chemokinesis in normal 
human neutrophils and that this mediation was inhibited by the specific PKC inhibitor GF 
109203x. 
None of these studies examined PKC directly. Instead the relationship between 
hyperglycemia and PKC was discovered indirectly by looking at the abnormal function of 
cells via the use of PKC inhibitors. As well, the studies did not compare the results for 
diabetics with those of healthy controls. The assessment of PKC activity in neutrophils is 
particularly important. Neutrophils are the primary phagocytic cell of the acute 
inflammatory response , and their study can shed light onto the microbiology of the 
relationship between diabetes and inflammatory diseases such as periodontitis. This 
paper attempts to provide insight about the dynamics of PKC (specifically the PKC~ll 
isoform) activity in the neutrophils of diabetics. 
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3. OBJECTIVES OF THE PRESENT STUDY 
1. To compare PKC activity of neutrophils in diabetics with healthy controls in-vivo 
2. To see if a correlation exists between diabetic persons' HbA 1c and/or fasting plasma 
glucose test results and the expression of activated PKC (phospho-PKC) in 
neutrophils. 
3. To discover the in vitro effect of the incubation of diabetic neutrophils in a high 
glucose (25mM) medium on activated PKC expression. 
4. To determine if neutrophils from diabetic and healthy controls express phospho-PKC 
similarly in response to incubation in a high glucose medium. 
5. To observe the auto-regulation in PKC activation of neutrophils while in the presence 
of glucose. 
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4. MATERIALS AND METHODS 
4.1 MATERIALS 
Cell Lysis Buffer: (Cell Signaling) 
20 mM Tris-HCl (pH 7.5), 
150 mM NaCl, 
1 mM Na2EDTA, 
1 mM EDTA, 
1% Triton X, 
2.5 mM sodium pyrophosphate, 
1 mM p-glycerophosphate, 
1 mMNa3VO4, 
1 µg/ml leupeptin 
Add lmM PMSF just before use. 
SDS Sample Loading Buffer (lX): (Cell Signaling) 
62.5 mM Tris-HCl (pH 6.8 at 25°C), 
2.0% w/v SDS, 
10% glycerol , 
50 mM DTT, 0.01% 
w/v bromophenol blue or phenol red 
Running Buffer: 25mM Tris base, 0.2 M glycine, 10% SDS (pH 8.3) 
TBS/T 0.05%: 20mM Tris base, 0.8% NaOCL , 0.05% Tween 20 
Transfer Buffer: 25mM Tris base, 0.2 M glycine, 10.0 % methanol (pH 8.5 
Blocking Buffer: TBS-T 0.05% with non-fat dry milk 5.0% 
Primary Antibody Buffer: TBS-T 0.05% with BSA 5.0% 
Secondary Antibody Buffer: TBS-T 0.05% with non-fat dry milk 5.0% 
Wash Buffer: TBS-T 0.05% 
Blotting Membrane: Polyvinylidine Difluoride (PVDF) membrane 
Antibodies: (Cell Signaling) 
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Primary Ab: Phospho-PKCa/~11 (Thr638/641) antibody detects PKCa only 
when phosphorylated at threonine 638 and PKC~ll only when phosphorylated at 
threonine 641. 
Secondary Ab: Anti-rabbit IgG, HRP-linked antibody Affinity purified goat 
anti-rabbit IgG (H&L) antibody is conjugated to horseradish peroxidase. 
Chemiluminescence: Cell Signaling 
LumiGLO ® reagent and peroxide 
4.2 METHODS 
SELECTION OF SUBJECTS 
This study was carried out on 13 diabetic and 13 healthy volunteers. For the portions of 
this study in which neutrophils of diabetics were compared to those of healthy controls, I 
used eleven matched pairs of diabetic and healthy control patients based on their age, 
gender , race and smoking. For non-comparative experiments I used the neutrophils of 
the additional two diabetic and two healthy subjects that were unmatched. 
At initial screening , diabetic volunteers met the following entry criteria: a minimum of 16 
teeth excluding third molars and the absence of systemic disorders. The periodontal status 
was evaluated on the basis of radiographic findings (bone level as a percentage of total 
tooth length) and clinical attachment loss. Metabolic control was ascertained on the basis 
of findings for HbA 1c, fasting plasma glucose (FPG), and total cholesterol. 
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ISOLATION OF NEUTROPHILS 
All patients' samples were obtained after approval of the Internal Review Board (IRB) at 
Boston University Medical Center. Peripheral venous blood was obtained using heparin 
(1 OU/ml) as anticoagulant. Neutrophils were isolated by using a discontinuous Ficoll-
Hypaque gradient system. Two milliliters (ml) of MonoPoly (Flow Laboratories, 
McLean, VA) and one ml of a mixture including Histopaque 1119 and Histopaque 1077 
(Sigma Chemical Co., St. Louis, MO) in 9: 1 ratio were deposited into 15-ml polystyrene 
culture tubes . Sequentially , one ml of Histopaque (separating medium) followed by 
4.5ml of peripheral blood was layered on top of the MonoPoly resolving medium 
(MPRM). Subsequently , the tubes were centrifuged at 500 X g for 30 min to separate the 
blood into its constituent layers representing neutrophils , erythrocytes , and monocytes. 
The neutrophil rich layer was collected , and contaminating erythrocytes were lysed with 
a hypotonic buffer containing NH 4Cl. The neutrophils were washed twice with 
phosphate-buffered saline (PBS , pH 7.4) then re-suspended in 50 ml PBS. The neutrophil 
concentration was determined with a hemocytometer and light microscope following 
which they were stored on ice. 
PREPARATION OF SAMPLES 
Neutrophils were aliquoted into labeled eppendorfs to get 5 million PMNs per condition. 
They were then incubated in accordance with the appropriate incubation protocol ( see 
Incubation). Following incubation , the cells were spun down at 2000 RPM for I 0 
minutes at 4°C in a microcentrifuge. The supernatant was discarded and 350ul of cold 
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cell lysis buffer was added. The samples were subsequently stored on ice for 5 minutes. 
Following this, they were sonicated, while on ice, three times for 5 sec. each time. After 
sonication, the samples were spun down at 10,000 rpm for 5 min at 4 °C in a 
microcentrifuge to separate the cell debris to a pellet. The pellet was discarded and the 
supernatant, representing the whole cell lysate, was stored in a labeled eppendorf at 
-80°C after the protein content was determined using a Bradford assay. 
INCUBATION 
After aliquoting the desired number of PMN s into eppendorfs, the cells were spun down 
to a pellet at 2000 rpm for 10 min at 4°C. The supernatant was discarded leaving the 
pellet behind. To this pellet 1.5 ml of either non-glucose DMEM or 25mM glucose 
DMEM was added along with 1 % (15µ1) bovine serum (to prevent PMN adhesion to 
surface of the eppendorf) and the cells were incubated at 3 7°C for a time ranging from 0 
to 6hrs. The choice of medium or time was dependant on the requirements of the 
experiment. 
PROTEIN SEPARATION 
Samples were removed from the -80°C freezer, thawed and placed on ice. A volume of 
sample equal to 30µg of total protein (as determined by Bradford assay) was aliquoted 
into an eppendorf. To this was added one half the protein sample volume of 3X SDS 
sample buffer (to dilute to 1 X). The mixture was boiled at 95-100°C for 5 minutes then 
cooled on ice. The cooled sample was microcentrifuged for 30 seconds to collect the 
sample at the bottom of the eppendorf. 
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Protein separation was accomplished with the Mini-PROTEAN 3 Electrophoresis system. 
Each sample was loaded into the stacking gel slots of a 10% discontinuous 
polyacrylamide gel leaving one lane reserved for the BIORAD protein ladder. The gel 
was run in running buffer at a constant 150 volts for 60 minutes. This resulted in the 
separation of the different proteins in the sample based on their weight in kilodaltans, 
which could be detected using the western immunoblotting technique. 
WESTERN BLOT 
After separation the gel was removed from between the glass plates and placed in transfer 
buffer for 15 minutes. In the meantime, a PVDF membrane was soaked in methanol for 
30 seconds , then in H20 for 2 minutes and finally in transfer buffer for a further 5 min. 
Following the incubation in transfer buffer the gel and PVDF membrane were assembled 
as per the Mini Trans-Blot Electrophoretic Transfer Cell instruction manual. The blot 
was run at a constant 1 00v for 60 minutes. 
Following transfer the membrane was sequentially incubated in 25 ml of Blocking Buffer 
for 1 hour at room temperature, 1 0µl primary antibody with 10ml antibody dilution 
buffer (1: 1000) overnight at 4 °C, and 5 µl secondary antibody in 10 ml of blocking buffer 
( 1 :2000) for 1 hour at room temperature. Each of the incubations was preceded by three 
5 minutes washes with TBS/T 0.05%. 
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DETECTION OF PROTEINS: PHOTOTOPE HRP WESTERN BLOT 
DETECTION SYSTEM 
The 1 ° antibody binds to the protein on the PVDF membrane. With the addition of the 2° 
antibody, HRP-conjugated complex is attached to the membrane. In the presence of 
hydrogen peroxide, horseradish peroxidase (HRP) converts luminal to an excited state 
that emits light upon return to its ground state. This light emission is captured on x-ray 
film. 
After the final wash with TBS/T 0.05% , the membrane was incubated in 10 ml of Ix 
LumiGLO ®: (0.5 ml 20X LumiGLO ®, 0.5 ml 20X Peroxide and 9.0 ml water) with 
gentle agitation for 1 minute at room temperature. Subsequently , the membrane was 
drained of excess developing solution, wrapped in plastic wrap and exposed to x-ray film. 
An initial exposure of 1 min was used. The time could then be adjusted according to 
clarity of the bands. 
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5. RESULTS 
PKC ACTIVITY IN UNCHALLENGED NEUTROPHILS 
The initial series of experiments sought to determine whether diabetic neutrophils had a 
greater base level of PKC activity when compared to age, race , and gender matched 
healthy controls. Neutrophils from 11 matched pairs of subjects were lysed immediately 
following separation from blood samples. An analysis of the W estem blots revealed 
average density readings of 0.25 +/- 0.03 AU and 0.42 +/- 0.05 AU for healthy controls 
and diabetics , respectively (figure 1 ). These results suggested that PKC activity in 
unchallenged neutrophils is greater in diabetic than in non-diabetic controls. 
0.6, 
HC 
HC OM 
DIABETIC 
FIGURE I PKC Activity is Greater for Diabetic, 
Unchallenged Neutrophils: Each bar represents the 
mean +/- SEM density of 11 separate experiments. 
Below is an immune blot for one subject. 
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PKC ACTIVITY AND IN VIVO GL YCEMIC LEVELS 
Closer examination of the results of these experiments revealed that the range of values 
for diabetic subjects was greater than that found for the healthy control (HC) subjects. 
Density values for diabetic PMNs were spread evenly between 0.17 to 0.798 AU. In 
contrast , the HC values only ranged from 0.11 to 0.53 AU with the majority of values 
falling close to the average of 0.25 AU. Thus , the DM standard of deviation was almost 
twice that ofHC (0.20 vs. 0.13 AU). 
We hypothesized that the greater range of values representing PKC activity was a 
consequence of the varied degrees of hyperglycemia of the diabetics . To this end, the 
density values were plotted against both the glycated hemoglobin and fasting plasma 
glucose test results ( figures 2 and 3) 
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FIGURE 2 High Correlation between PKC 
Activity and FPG: R2=0.9379 (straight line 
represents the trend line for the series.) 
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These figures show that neutrophil PKC activity is strongly correlated to FPG (R2 = 
0.9379) but only moderately correlated to glycated hemoglobin (R2 = 0.7385). The blot 
in figure 4 illustrates that even as HbA 1c values remain similar PKC activity is increased 
with increasing fasting plasma glucose values. 
FIGURE 4 Immune Blot of PKC Activity, Comparison with 
HbA 1c and FPG: Immune blot shows PKC activity of 3 subjects 
against their FPO and HbAlc test results. 
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PKC ACTIVITY AND IN VITRO GL YCEMIC LEVELS 
To lend further support for the hypothesis that hyperglycemia is responsible for increased 
PKC activity in diabetics ; a series of experiments was designed to test neutrophil PKC 
activity in vitro. The first set of experiments compared PKC activity in unchallenged and 
challenged neutrophils from five diabetic subjects. Unchallenged neutrophils were lysed 
immediately following separation while challenged neutrophils were incubated in 25mM 
glucose medium. The results of this experiment clearly show increased activity in 
response to glucose (figure5). 
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FIGURE 5 High Glucose Increases PKC 
Activity in Diabetic Neutrophils: Each 
bar represents mean +/- SEM densit y of 5 
experiments. Below is the immunoblotting 
from one subject. 
There was a mean increase of 213% in PKC activity following two hours of incubation 
with glucose. This experiment was then repeated on the neutrophils of healthy controls to 
determine whether this phenomenon was related to genetic or developmental defects in 
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the neutrophils of diabetics or whether it was a response to the environment of high 
glucose levels. Here as well there was a significant increase in activity (figure 6). The 
results of experimentation on eight HC subjects showed a 218% increase. This figure is 
also notable in that both diabetic and healthy control neutrophils showed the same 
percent increase in PKC activity. 
1.8 ~ 
1.6 ~ 
1.4 ~ 
HEALTHY CONTROL 
,..._ 1.2 ~ 
::J Figure 6 High Glucose Increases PKC 
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Each bar represents mean +/- SEM densit y of 
5 experiments. Below is the immunoblotting 
from one subject. 
Once it was observed that both sets of neutrophils reacted similarly to a glucose challenge 
the next set of experiments was designed to establish that the increase in PKC activity 
was related to the presence of glucose and not the actual process of incubation. To this 
37 
end, the neutrophils were incubated in either glucose or a non-glucose containing 
medium. Here as well glucose in the medium resulted in increased activity (figures 7,8). 
FIGURE 7 High Glucose Medium Increases PKC Activity in Healthy Control 
Neutrophils: Each bar represents the mean +/- SEM density of 4 healthy control subjects . 
Below is the immune blot of one subject. 
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FIGURE 8 High Glucose Medium Increases PKC Activity in Diabetic Neutrophils: 
Each bar represents the mean +/- SEM density of 5 diabetic subjects. Below is the immune 
blot of one subject. 
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A final set of experiments was designed to determine if there was any deregulation of 
PKC activity. These experiments showed that greater than 15 minutes of incubation with 
glucose was required to activate PKC. In addition , no significant deregulation could be 
observed with up to 6 hours of glucose incubation (figure 9) 
FIGURE 9 PKC Activity in Neutrophils in the Presence of Glucose: Below is 
an immune blot of one healthy control subject. 
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6. DISCUSSION 
In this study we demonstrate that neutrophils from diabetics display increased levels of 
activated PKC that correlates well with increasing fasting plasma glucose values. 
Further , we show that the increased activity is the result of the state of hyperglycemia and 
occurs in neutrophils from diabetic and non-diabetics alike. 
The first set of experiments was designed to compare the levels of activated PKC in 
unchallenged neutrophils in diabetics with those in healthy controls. These showed 
significantly higher activity for diabetics than healthy controls (0.42 +/- 0.05 AU and 
0.25 +/- 0.03 AU). It was noted that the diabetic neutrophils also displayed a greater 
range of PKC activity. To provide an explanation for this phenomenon hyperglycemia 
was considered. To this end the individual density values for the diabetic subjects were 
plotted against the results of both HbA I c and fasting plasma glucose (FPG) test results. 
This plot found a link between the test results and PKC activity , revealing a higher 
correlation with FPG than HbA 1c (R2= 0.9379 vs. 0.7385 , respectively) 
Having found that hyperglycemia could activate PKC in vivo a new set of experiments 
was designed to observe this effect in vitro. These experiments also resulted in increased 
PKC activity ; diabetic neutrophils incubated in 25mM glucose medium for 2 hrs resulted 
in a 215% increase. When these experiments were repeated on healthy control 
neutrophils a similar (218%) upregulation of PKC activity was revealed. Of particular 
note was that both healthy control and diabetic neutrophils experienced the same 
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percentage upregulation. To rule out the procedure of incubation as a factor in PKC 
upregulation the in vitro hyperglycemia experiments were repeated using neutrophils 
incubated in a non-glucose containing medium as well. These experiments confirmed the 
previous findings of PKC upregulation in a hyperglycemic environment. 
Additional experiments examined the observed glucose-induced upregulation with 
respect to the duration of incubation. The results show that PKC activation results within 
15 minutes and continues to rise without any significant deregulation for a period of up to 
6 hours. These results combined with the correlation of basal PKC activity with plasma 
glucose suggest that neutrophils need not be in a hyperglycemic environment at the time 
of their genesis but rather can react to glucose spikes. Cumulatively, the data collected 
for this thesis reinforces the hypothesis that PKC activation in diabetes is largely 
accounted for by hyperglycemia. 
Other papers have also reported the hyperglycemia-induced activation of PKC in various 
cells and tissues of diabetics. Activity is increased in the retina[96 , 97], aorta and heart 
[94, 98], renal glomeruli [95], and liver cells [l 08] as well as in cultured vascular cells or 
tissues exposed to elevated levels of glucose [94, 99]. Studies examining blood cells in 
particular have had similar findings. Assert el al [109] and Pirags et al [110] concluded 
that hyperglycemia could increase PKC activity in platelets. This conclusion was also 
reached by the previously mentioned work of Saiepour [105, 109] and Oldenborg [107] 
on normal neutrophils , and that of Ceo lotto [ 111] on monocytes. 
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Ceo lotto's in vivo study on monocytes is particularly analogous as it parallels much of the 
in-vitro results presented in this paper on neutrophils. In his study, conditions of 
hyperglycemia and euglycemia were created in human subjects using glucose or insulin 
infusions prior to acquiring the blood sample. He evidenced the PKC activity in 
circulating monocytes from both diabetics and healthy subjects is greater when their 
blood is hyperglycemic and returns to lower levels after insulin infusions and a 
subsequent return to euglycemia. Ceolotto also found a high correlation between basal 
(unchallenged by glucose infusion) diabetic PKC activity and fasting plasma glucose. 
This correlation indicates that immediate glucose levels are more relative with respect to 
PKC activation since in contrast, HbA 1 c values represent a three-month average of 
glycemia. Since monocytes have a lifespan of a few months the correlation also implies 
that that activity can be deregulated. The latter implication cannot be made for 
neutrophils as their lifespan is only a few hours to a few days; HbA 1 c would not be 
expected to be relevant to an understanding of PKC-glucose dynamics in these cells. This 
result may seem at first to contradict the findings by the DCCT and UKPDS that HbA I c 
levels are a reliable indicator of metabolic control but as explained above these levels 
represent 3 month averages while I was interested in the immediate response of short-
lived neutrophils. 
One recent study appears to contradict the results presented here. Padival [112] found 
that glomerular mesangial cells incubated in high glucose medium resulted in a 
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predominantly cytosolic localization of PKC~l while stimulation with PMA resulted in 
membrane localization. Though this is in contrast to the research of Amiri [113] on 
mesangial cells and my findings with PKC~ll in neutrophils , it is in keeping with 
previous work that shows that PMA stimulates more PKC isotypes than hyperglycemia 
[85, 88]. It is also likely that the PKC isotypes that are sensitive to hyperglycemia are 
tissue and cell specific. 
Systemic factors modify periodontitis principally through their effects on the normal 
immune and inflammatory mechanisms. As discussed previously , PMN function is 
altered in diabetic patients. Defects in adherence [66, 67] , chemotaxis [68-70] , or 
phagocytosis [71, 72] have all been reported. Hyperglycemia-upregulation of PKC has 
also been implicated in alterations in adherence [ 102, 106], chemotaxis [ 107, 114 ], 
phagocytosis [105 , 114], as well as oxidative killing [65, 115-117]. Thus , PKC activation 
plays a role in the dysfunction of neutrophils in diabetics. Such alterations in the normal 
functioning of neutrophils impair the body's immunological response to bacterial insult 
or physical trauma ; neutrophil mediated damage is seen in both diabetes and periodontal 
diseases as well as other inflammatory conditions such as rheumatoid arthritis and 
inflammat r y bowel disease[34]. 
The increased severity of periodontal complications observed in diabetics provides a link 
between the upregulation of PKC due to hypergl ycemia and periodontal disease. Beyond 
its role in neutrophils , upregulation of PKC is involved in the pathogenesis of 
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periodontitis via intracellular signaling cascades leading to the production of enzymes 
and cytokines and altered function of cells within the periodontium. 
Kontny et al [118] studied one such cascade by examining the cytosol-to-membrane 
translocation of PKC with respect to cytokine production in human monocytes cultured in 
vitro. The researchers found that the activation of PKC resulted in the induction of 
signaling cascades leading to TNF-a, IL-1 ~, and IL-6 synthesis. TNF-a and IL-1 ~ can 
stimulate prostaglandin E2 (PGE 2) production. Accumulating evidence indicates that 
prostaglandins play an important role in the pathogenesis of periodontal disease [3 7, 
119]. Experimental evidence from Yucel-Lindeberg et al [120] showed that PMA 
activation of PKC enhanced the stimulatory effect of TNF-a and IL- I~ on PGE 2 
production in fibroblasts. 
Cytokines are also involved with one of the enzymes affected by PKC, matrix 
metalloproteinase (MMP) [121, 122]. MMPs play an important role in tissue remodeling 
and in the pathology of inflammatory diseases including periodontitis. Domeij et al [ 123] 
looked a1/ he contribution of the cytokine IL- I~ on the interaction of PKC with MMP-1. 
Activati f n of PKC stimulated the production of both MMP-1 and tissue inhibitor of 
metalloproteinase-1 (TIMP-1 ). In addition, treatment of the cells with IL-1 ~ 
synergistically increased the stimulatory effect of PKC on MMP-1 production but did not 
affect TIMP-1. Thus it was concluded that IL-I~ regulates PKC-stimulated MMP-1 and 
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TIMP-1 production differently in human gingival fibroblasts and that this discrepancy in 
production could contribute to tissue destruction in periodontal diseases. 
Disruption of the mechanisms of bone metabolism can also contribute to periodontal 
disease progression. Research on tissue destruction in alveolar bone has led to the 
hypothesis that osteoblasts act in response to formative and resorbtive stimuli. These 
stimuli involve intracellular signaling controlled in part by PKC. Such interaction with 
PKC is postulated to increase osteoclastic recruitment and activity as well as osteoclastic 
proliferation. The accumulated evidence of these studies demonstrates that 
hyperglycemia and PKC in particular has a multifactorial affect upon the severity and 
progression of periodontal disease. 
Future studies could attempt to ascertain which of the PKC isoforms present in 
neutrophils are sensitive to hyperglycemia and elucidate the subsequent PKC substrate 
activity. One could also examine whether once upregulated PKC activity could be 
deregulated in the presence of euglycemic conditions. Diabetics can experience wide 
fluctua~ s in blood glucose levels, thus it would be useful to know if a transient glucose 
spike would permanently elevate PKC activity for the life of the neutrophils or if the 
PMNs could be expected to return to normal function when glucose levels were restored 
to normal. Given the emerging and cell-specific functions of the PKCs in the regulation 
of cellular immune responses , selective inhibition of individual PKC isoenzymes might 
be effective in treating a wide range of human diseases associated with aberrant immune 
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functions. From a purely clinical, periodontal point of view it may be prudent to 
concentrate specifically on the role of PKC in periodontitis and whether inhibition of its 
upregulation can safely ameliorate periodontal parameters such as bleeding, probing 
depths, and attachment loss. 
In conclusion, the findings of this dissertation were that the activity of PKC~ll isoform in 
neutrophils of diabetics is increased and maintained chronically additionally, this effect is 
determined by hyperglycemia per se, independent of whether the subject is type 1 or 2 
diabetic or non-diabetic. 
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